British consumer healthcare group Haleon on Thursday said 2025 revenue and profit growth would be weighted to the second half ...

Haleon posted £11.23B in FY24 revenue, with 5% organic growth. 2025 guidance expects 4-6% organic growth, with profit gains ...

UK's Haleon reported annual profit in line with market expectations on Thursday, as the Sensodyne toothpaste and Advil ...

Haleon disappointed investors after the Sensodyne toothpaste maker said 2025 revenue growth would be weighted to the second half of the year.

Haleon projects a gradual revenue and profit ... The company, which makes Sensodyne toothpaste, ENO antacids and Centrum multivitamins, projected organic revenue would grow between 4 per cent ...

Consumer healthcare giant Haleon has reported a strong financial performance for 2024, with organic revenue growth of five ...

Sensodyne-maker Haleon’s annual profits rose in line with expectations last year as it got a boost in demand for its oral ...

Learn more about whether Haleon plc or Intra-Cellular Therapies, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

HALEON PLC (LON:HLN) shares slid 3% in London on Thursday after the Sensodyne toothpaste maker said its revenue growth for 2025 would be weighted toward the second half of the year.

Pfizer to sell $3 billion stake in Sensodyne maker Haleon Pfizer will sell shares worth 2.50 billion pounds ($3.05 billion) in Haleon , lowering its stake in the British consumer healthcare ...